ALBERTDAVD850.00

Albert David Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersVALIANTLABHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹485 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations362.5345.8333.6364.4
Other Income57.629.67.513.4
Total Income420.0375.3341.1377.7
Expenses
+ Cost of Materials Consumed63.970.259.965.0
+ Purchases of Stock-in-Trade64.360.549.051.5
+ Changes in Inventories-1.8-14.35.08.3
+ Employee Benefit Expense88.4109.0102.599.6
+ Finance Costs0.30.42.62.6
+ Depreciation & Amortisation6.87.09.89.7
+ Other Expenses100.8117.4111.8113.2
Total Expenses322.7350.1340.5349.9
EBITDA46.93.05.526.8
EBIT40.1-3.9-4.317.1
Profit
PBT before Exceptional Items97.325.20.527.9
Pretax Income97.325.20.527.9
+ Current Tax15.85.93.34.5
+ Deferred Tax6.12.1-1.30.8
Tax Expense21.98.02.05.3
Net Income75.417.2-1.522.6
+ Net Income — Continuing Ops75.417.2-1.522.6
+ Other Comprehensive Income1.1-1.13.42.6
Total Comprehensive Income76.516.11.925.1
Per Share
Basic EPS132.1530.14-2.6239.53
Diluted EPS132.1530.14-2.6239.53
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.13.42.6
+ Items NOT to be Reclassified to P&L1.1-0.44.53.3
+ Tax on Items NOT to be Reclassified0.71.10.8
+ Tax on Items NOT to be Reclassified — alt tag-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations132.1530.14-2.6239.53
Diluted EPS — Continuing Operations132.1530.14-2.6239.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit236.1229.5219.7239.6
Gross Margin %65.1366.3765.8765.76
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)97.325.20.527.9
Net Income Adj (tax-effected)75.417.2-1.522.6
EPS Adj132.1530.14-2.6239.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital5.75.75.75.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.